SLC5A2 and hyperuricemia: In general, the kidney accounts for approximately 70% of urate elimination, and SGLT2 inhibitors could facilitate glucose transporter 9 excretion of more urine uric acid in exchange for glucose reuptake by increasing glucose concentrations in glomerular filtrate.7 Because hyperuricemia is accepted as the most important risk factor for development of gout,8 we speculated whether SGLT2 inhibitor use influences the risk of gout.